Compound details
1-deoxytetradecasphinganine
| Compound ID | CDAMM00374 |
|---|---|
| Common name | 1-deoxytetradecasphinganine | IUPAC name | (2S,3R)-2-aminotetradecan-3-ol |
| Molecular formula | C14H31NO |
| Retention time | 55.774 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 230.248 | Theoretical mz | 230.248 |
| Error | 1.55 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 7.37 |
| Inchi key | WMUMHAZHWIUBPN-UONOGXRCSA-N |
|---|---|
| Smiles | OC(CCCCCCCCCCC)C(N)C |
| Superclass | Organic nitrogen compounds |
| Class | Organonitrogen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P07327 | ADH1A | Alcohol dehydrogenase alpha chain | T65570 | SEA |
| P15144 | ANPEP | Aminopeptidase N | T67272 | SEA |
| Q9NYA1 | SPHK1 | Sphingosine kinase 1 | T86014 | SwissTargetPrediction |
| P00813 | ADA | Adenosine deaminase | T03661 | SEA |
| P0DJD9 | PGA5 | Pepsin A | T17863 | SEA |
| P21453 | S1PR1 | Sphingosine 1-phosphate receptor Edg-1 | T13852 | SEA |
| Q9NRA0 | SPHK2 | Sphingosine kinase 2 | T31989 | SEA |
| Q99500 | S1PR3 | Sphingosine 1-phosphate receptor Edg-3 | T11241 | SEA |
| P43657 | LPAR6 | Lysophosphatidic acid receptor 6 | T13484 | SEA |
| O95136 | S1PR2 | Sphingosine 1-phosphate receptor Edg-5 | T47888 | SEA |
| O95977 | S1PR4 | Sphingosine 1-phosphate receptor Edg-6 | T17523 | SEA |
| Q9UBY5 | LPAR3 | Lysophosphatidic acid receptor Edg-7 | T95923 | SEA |
| Q99677 | LPAR4 | Lysophosphatidic acid receptor 4 | T58130 | SEA |
| O95749 | GGPS1 | Geranyltranstransferase | T86528 | SEA |
| Q4U2R8 | SLC22A6 | Solute carrier family 22 member 6 (by homology) | T70680 | SEA |
| O60603 | TLR2 | Toll-like receptor 2 | T82078 | SEA |
| O95749 | GGPS1 | Geranyltranstransferase | T86528 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T65570 | DI0139 | Exposure to noxious substances harmful effect | [ICD-11: NE61] | P07327 | ADH1A |
| T67272 | DI0351 | Psoriasis | [ICD-11: EA90] | P15144 | ANPEP |
| T86014 | DI0321 | Ovarian cancer | [ICD-11: 2C73] | Q9NYA1 | SPHK1 |
| T86014 | DI0353 | Psychoactive substances use disorder | [ICD-11: 6C4G] | Q9NYA1 | SPHK1 |
| T03661 | DI0016 | Adaptive immunity immunodeficiency | [ICD-11: 4A01] | P00813 | ADA |
| T03661 | DI0245 | Malignant haematopoietic neoplasm | [ICD-11: 2B33] | P00813 | ADA |
| T03661 | DI0249 | Mature B-cell leukaemia | [ICD-11: 2A82] | P00813 | ADA |
| T13852 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P21453 | S1PR1 |
| T13852 | DI0419 | Ulcerative colitis | [ICD-11: DD71] | P21453 | S1PR1 |
| T31989 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | Q9NRA0 | SPHK2 |
| T11241 | DI0062 | Breast cancer | [ICD-11: 2C60-2C6Y] | Q99500 | S1PR3 |
| T47888 | DI0419 | Ulcerative colitis | [ICD-11: DD71] | O95136 | S1PR2 |
| T95923 | DI0146 | Fibrosis | [ICD-11: GA14-GC01] | Q9UBY5 | LPAR3 |
| T95923 | DI0399 | Systemic sclerosis | [ICD-11: 4A42] | Q9UBY5 | LPAR3 |
| T86528 | DI0057 | Bone paget disease | [ICD-11: FB85] | O95749 | GGPS1 |
| T86528 | DI0237 | Low bone mass disorder | [ICD-11: FB83] | O95749 | GGPS1 |
| T86528 | DI0267 | Mineral excesses | [ICD-11: 5B91] | O95749 | GGPS1 |
| T86528 | DI0281 | Musculoskeletal disorder | [ICD-11: FA00-FC0Z] | O95749 | GGPS1 |
| T70680 | DI0167 | Gout | [ICD-11: FA25] | Q4U2R8 | SLC22A6 |
| T70680 | DI0206 | Inborn purine/pyrimidine/nucleotide metabolism error | [ICD-11: 5C55] | Q4U2R8 | SLC22A6 |
| T70680 | DI0310 | Ocular disease | [ICD-11: N.A.] | Q4U2R8 | SLC22A6 |
| T82078 | DI0346 | Prostate cancer | [ICD-11: 2C82] | O60603 | TLR2 |
| T86528 | DI0057 | Bone paget disease | [ICD-11: FB85] | O95749 | GGPS1 |
| T86528 | DI0237 | Low bone mass disorder | [ICD-11: FB83] | O95749 | GGPS1 |
| T86528 | DI0267 | Mineral excesses | [ICD-11: 5B91] | O95749 | GGPS1 |
| T86528 | DI0281 | Musculoskeletal disorder | [ICD-11: FA00-FC0Z] | O95749 | GGPS1 |